Lansforsakringar Fondforvaltning AB publ reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 33,101 shares of the biopharmaceutical company’s stock after selling 4,987 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Regeneron Pharmaceuticals were worth $25,575,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Tred Avon Family Wealth LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.5% in the 1st quarter. Tred Avon Family Wealth LLC now owns 507 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 17 shares in the last quarter. McLean Asset Management Corp acquired a new position in Regeneron Pharmaceuticals during the first quarter worth about $210,000. Apollon Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 7.4% during the first quarter. Apollon Wealth Management LLC now owns 3,831 shares of the biopharmaceutical company’s stock worth $2,960,000 after acquiring an additional 264 shares during the last quarter. Patton Fund Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $302,000. Finally, Janney Montgomery Scott LLC grew its position in shares of Regeneron Pharmaceuticals by 16.4% in the first quarter. Janney Montgomery Scott LLC now owns 13,078 shares of the biopharmaceutical company’s stock valued at $10,105,000 after purchasing an additional 1,845 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on REGN shares. Leerink Partners reissued a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a report on Monday, May 18th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Citigroup cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $900.00 to $700.00 in a report on Monday, May 18th. Finally, Canaccord Genuity Group reduced their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.
Regeneron Pharmaceuticals Stock Performance
Regeneron Pharmaceuticals stock opened at $623.54 on Wednesday. The stock has a fifty day moving average price of $658.68 and a 200 day moving average price of $727.47. Regeneron Pharmaceuticals, Inc. has a 52 week low of $521.00 and a 52 week high of $821.11. The firm has a market capitalization of $65.92 billion, a P/E ratio of 15.19, a PEG ratio of 1.39 and a beta of 0.25. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period last year, the company earned $8.22 EPS. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.
Insider Transactions at Regeneron Pharmaceuticals
In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
